0.780
0.01 (1.14%)
| Penutupan Terdahulu | 0.771 |
| Buka | 0.775 |
| Jumlah Dagangan | 623,037 |
| Purata Dagangan (3B) | 832,731 |
| Modal Pasaran | 100,727,880 |
| Harga / Buku (P/B) | 1.92 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| EPS Cair (TTM) | -0.200 |
| Nisbah Semasa (MRQ) | 12.67 |
| Aliran Tunai Operasi (OCF TTM) | -22.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.54 M |
| Pulangan Atas Aset (ROA TTM) | -21.67% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Atossa Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.07% |
| % Dimiliki oleh Institusi | 26.58% |
| Julat 52 Minggu | ||
| Median | 8.00 (925.90%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Ascendiant Capital | 08 Dec 2025 | 8.00 (925.90%) | Beli | 0.794 |
| 22 Sep 2025 | 7.75 (893.84%) | Beli | 0.830 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |